Pictet North America Advisors’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-10,141
Closed -$2.47M 126
2021
Q2
$2.47M Buy
10,141
+209
+2% +$51.4K 0.26% 55
2021
Q1
$2.47M Buy
9,932
+2,123
+27% +$507K 0.29% 51
2020
Q4
$1.79M Buy
7,809
+594
+8% +$137K 0.23% 58
2020
Q3
$1.83M Buy
7,215
+303
+4% +$75.1K 0.26% 54
2020
Q2
$1.63M Buy
6,912
+27
+0.4% +$6.16K 0.23% 62
2020
Q1
$1.4M Buy
6,885
+1,507
+28% +$329K 0.24% 65
2019
Q4
$1.3M Buy
5,378
+296
+6% +$65.2K 0.16% 75
2019
Q3
$983K Buy
5,082
+554
+12% +$106K 0.13% 89
2019
Q2
$834K Sell
4,528
-624
-12% -$112K 0.12% 90
2019
Q1
$979K Hold
5,152
0.15% 80
2018
Q4
$1M Hold
5,152
0.09% 76
2018
Q3
$1.07M Buy
5,152
+1,929
+60% +$380K 0.14% 79
2018
Q2
$595K Hold
3,223
0.09% 87
2018
Q1
$549K Buy
3,223
+75
+2% +$13.8K 0.08% 86
2017
Q4
$547K Buy
3,148
+1,204
+62% +$213K 0.08% 85
2017
Q3
$362K Hold
1,944
0.06% 99
2017
Q2
$335K Hold
1,944
0.06% 102
2017
Q1
$319K Hold
1,944
0.05% 104
2016
Q4
$284K Hold
1,944
0.06% 91
2016
Q3
$324K Sell
1,944
-4,000
-67% -$676K 0.08% 81
2016
Q2
$904K Buy
+5,944
New +$924K 0.21% 65

Other funds holding AMGN

Pictet North America Advisors's AMGN Position: Q3 2021 in Review

Pictet North America Advisors sold out of Amgen (AMGN) in Q3 2021, closing a stake of 10,141 shares — an estimated $2.47M sold.

Pictet North America Advisors first reported a position in AMGN in Q2 2016 and held it in 21 quarters. The position peaked at $2.47M in Q2 2021. 2,131 funds tracked by Wall St. Rank hold AMGN as of Q3 2021.

  • Pictet North America Advisors reported no remaining Amgen position as of Q3 2021 after selling out during the quarter.
  • Pictet North America Advisors sold 10,141 Amgen shares in Q3 2021, an estimated $2.47M.
  • Pictet North America Advisors first reported a position in Amgen in Q2 2016 and held it in 21 quarters.
  • Pictet North America Advisors's Amgen position peaked at $2.47M in Q2 2021.
  • 2,131 funds tracked by Wall St. Rank held Amgen as of Q3 2021.

Based on Pictet North America Advisors's 13F filing for Q3 2021, filed 10 Nov 2021.